Shoulder injections with autologous conditioned serum reduce pain and disability in glenohumeral osteoarthritis: longitudinal observational study

Background Currently, non-surgical treatments for glenohumeral osteoarthritis (GH-OA) mainly aim to reduce pain. Autologous conditioned serum (ACS), Orthokine, an interleukin-1 inhibitor from the patient's own blood has anti-inflammatory effect. The objective was determine whether intra-articular injections of this ACS improved symptoms in patients with GH-OA and delayed need a shoulder replacement. Methods A total 36 consecutive patients, 40 shoulders, OA received up 6-weekly were included. Imaging GH-OA, range motion, visual analogue scale (VAS) pain, Shoulder Pain And Disability Index (SPADI), American Elbow Surgeons Constant scores assessed pre-injection post treatment at 3 months. At minimum 2 years, VAS SPADI anyone had progressed replacement recorded. Results Outcomes months post-ACS demonstrated on average statistically significant improvement (P < 0.05) all measurements: (54.3 ± 21.5 vs 43.7 23.7), score (50.5 14.1 57.1 17.4), pain (4.8 2.2 3.7 2.4) motion. Of these, 16 shoulders replacement, nine cases quickly (0.6 0.2 years) seven by 3.1 1.7 years. other 18 (58.0 19.6 31.8 21.4; P 0.01) no progression 3.6 1.0 years follow-up. There correlation glenoid Walch or joint space clinical outcome parameters. Conclusion can disability, postpone